Kanjinti (Trastuzumab (trastuzumab) — Uses, Dosage, Side Effects & Safety

Drug class: Monoclonal Antibody, Antineoplastic Agent

Overview

Kanjinti (trastuzumab) is a targeted therapy used to treat certain types of breast cancer and stomach cancer that overexpress the HER2 protein. It is most commonly prescribed for HER2-positive breast cancer, either alone or in combination with other chemotherapy agents. Trastuzumab works by binding to the HER2 receptor on cancer cells, blocking their growth signals and helping the immune system destroy these cells. This targeted action helps slow or stop the progression of cancer. Key points for patients: Kanjinti is given as an injection by a healthcare professional, usually in a hospital or clinic. It is important to attend all scheduled appointments and report any side effects, especially heart problems or allergic reactions, to your doctor.

Therapeutic uses

• HER2-overexpressing breast cancer (adjuvant and metastatic)
• HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
• HER2-overexpressing metastatic colorectal cancer (in combination with other agents)

Common side effects

• Cardiomyopathy
• Infusion-related reactions
• Diarrhea
• Nausea
• Fatigue
• Neutropenia
• Fever

Frequently Asked Questions about Kanjinti (Trastuzumab

What is Kanjinti (trastuzumab) used for?

Kanjinti is used to treat HER2-positive breast cancer and HER2-positive metastatic gastric cancer. It is often used in combination with other chemotherapy drugs.

How does Kanjinti work?

Kanjinti targets the HER2 receptor on cancer cells, blocking signals that cause cell growth and marking the cells for destruction by the immune system.

What are the most serious side effects of Kanjinti?

The most serious side effects include heart failure, severe allergic reactions, lung problems, and infusion-related reactions.

Can I take Kanjinti if I am pregnant or breastfeeding?

No. Kanjinti can harm an unborn baby and is not recommended during pregnancy or breastfeeding. Use effective contraception during treatment and for 7 months after the last dose.

How is Kanjinti administered?

It is given as an intravenous infusion or subcutaneous injection by a healthcare professional in a clinical setting.

What should I do if I miss a dose?

Contact your healthcare provider immediately to reschedule your missed dose. Do not try to administer the medication yourself.

Are there any medicines I should avoid while taking Kanjinti?

Avoid other medications that can affect heart function, especially certain chemotherapy drugs. Always inform your doctor about all medicines you are taking.

Educational information only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.